Krakow, Poland – 5 June 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will exhibit at the upcoming 20th Annual Drug Discovery Summit, taking place on June 11-12, in Berlin, Germany.
Throughout the whole event, Selvita’s team will be available at booth #8. It is a great opportunity to meet our representatives on-site and discuss Selvita’s capabilities in the area of integrated drug discovery services.
To contact Selvita’s delegates at this conference, please email us at email@example.com.
Annual Drug Discovery Summit attracts 350+ delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions. It’s an occasion to take advantage of 60+ presentations, case studies and panel discussions focused on the key issues in drug discovery and medicinal chemistry.
Additional information is available on the conference website at
Selvita Services Segment
Selvita Services Segment is a drug discovery and development partner for the pharmaceutical and biotechnology industries. It provides integrated drug discovery support starting from hit identification, hit to lead, lead optimization phase up to nomination of a preclinical candidate. The broad range of services includes medicinal and computational chemistry, custom synthesis and scale-up, in vitro pharmacology, structural biology, protein chemistry, ADME/DMPK as well as a comprehensive offer of analytical testing for APIs and drug products. In addition, Selvita Services Segment has extensive expertise in comparability studies of biosimilar drugs. Its laboratories are both GLP- and GMP-certified.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the U.S (Greater Boston, San Francisco Bay), and in the U.K. (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from the U.S. and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).